Navigation Links
Biomatrica's PCRboost(TM) Enables 5-Fold Improvement in Amplification of Difficult Samples
Date:3/12/2008

SAN DIEGO, March 12 /PRNewswire/ -- Biomatrica, the leader in room temperature biological sample stabilization, announced the introduction of PCRboost, a reagent that enhances PCR and RT-PCR performance 5-fold or more by improving sensitivity and specificity during amplification of genomic DNA or RNA templates.

PCRboost makes it easy for scientists to amplify templates that are traditionally difficult to amplify and present in limited quantities. At the same time the number of cycles and amount of polymerase used are reduced, resulting in significant time and cost savings.

"With PCRboost, I obtained at least a 5-fold increase in the amplification of formalin-fixed paraffin embedded (FFPE) cervical cancer tissue samples compared to using water in a standard master mix," said Mina Kalantari, Ph.D., University of California, Irvine. "I start out with very small amounts of degraded DNA and then perform bi-sulfite modification for DNA methylation analysis, which leads to further degradation. Using PCRboost, I am now able to see bands that were invisible without it."

PCRboost greatly improves the amplification of difficult samples, enhancing the yield, specificity and consistency of the final product. There are no changes needed to existing PCR and RT-PCR protocols -- researchers simply replace the water in the reaction with PCRboost. Amplification is drastically improved for all samples including trace samples (less than or equal to 1 ng), degraded samples, low copy transcripts, multiplexing (i.e., STR analysis) and samples containing inhibitory factors.

"PCRboost is very easy to use -- you just add the reagent instead of water to your reaction mixture. I love the outcome!" states Kalantari.

PCRboost is currently available in three formats: a Trial Kit, containing 150 ul of PCRboost; a 1 ml tube; and a 10 ml bottle. All three sizes are available for purchase at http://www.biomatrica.com.

About Biomatrica(R), Inc.

Biomatrica (http://www.biomatrica.com) is a San Diego-based biostability company that provides innovative technologies for stabilizing, processing, storing and shipping biological samples at room temperature. The core technology is designed for use in preserving complex biological samples and assays and is based on the principles of anhydrobiosis ("life without water"), a natural mechanism that allows multicellular organisms to survive extreme environments. Biomatrica's current products stabilize DNA and RNA with no sample degradation, thus labs can reduce their reliance on freezers and drastically reduce shipping costs. Biomatrica products are used in laboratories performing life science research, from pharmaceutical and biotechnology companies to academic research and forensics laboratories. Custom services to stabilize additional sample types are also available. Biomatrica also offers SampleWare(R) software, an easy-to-use, customizable laboratory management database that provides scientists with the means to store and organize their sample data, and directly supports samples stabilized by Biomatrica technology.


'/>"/>
SOURCE Biomatrica
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery
2. MEDEA+ Noblanc award highlights improvements in microelectronics
3. China Biologic Products Gains Financial Support from Shandong Provincial Government on the Improvement of Production Facilities
4. Synthetech Earns National Recognition for Performance Improvement Program
5. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
6. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
7. Difficult to Treat Erectile Dysfunction Patients
8. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
9. IBM and Imago find a crucial difficulty in semiconductor device scaling
10. McGill University Purchases GenVaults Personal Archive System to Manage Rare Cancer Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... --  iSpecimen ®, the marketplace for human ... (DPS), a full-service anatomic pathology reference lab serving ... , has joined a program offered by iSpecimen ... to make human biospecimens and associated data available to ... in 2015 as a collaboration between iSpecimen and DHIN, ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com ... ... cancer conditions are being pressured as of late due to ... cancer pain management has a dramatic impact on patient,s quality ... and development activities for identifying new forms of opioid formulations ...
(Date:3/22/2017)... March 22, 2017   Boston Biomedical , an ... designed to target cancer stemness pathways, today announced its ... as Chief Executive Officer, effective April 24, 2017. ... J. Li , M.D., FACP, who has led Boston ... Under his leadership, Boston Biomedical has grown from a ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Premier executive ... & Life Science Search Firm by Hunt Scanlon Media. , Hunt Scanlon ... and the most widely referenced global news source in the human capital sector. , ...
Breaking Biology Technology:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
Breaking Biology News(10 mins):